Regular Member Biocon Biologics

Member Spotlight: Biocon Biologics

Investment, Innovation, Growth and Affordability

Biocon Biologics has emerged as a leading biosimilars player in the U.S. and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases. As a fully integrated biosimilar company, it is singularly focused on the development, manufacturing, distribution, and commercialization of the highest quality biosimilars in the world.

Founded by Kiran Mazumdar Shaw in 1978, Biocon has evolved from manufacturing speciality enzymes to pharmaceuticals like statins and immunosuppressants, to discovering, developing, and producing lifesaving biotherapeutics. Today, the company is ranked among the top 15 biomanufacturing companies in the world.

To further strengthen its leadership position in the global biosimilars industry, Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris and announced the integration of the Company’s North America biosimilar business. The acquisition is helping to expand the availability of high-quality biosimilars and patient services here in the United States and around the world, providing patients and healthcare professionals with more accessible and affordable options to treat diabetes, cancer, autoimmune diseases, and soon other key therapeutic areas.

Now, with one of the broadest and deepest biosimilar portfolios in the industry, patients worldwide benefit from Biocon Biologics’ commercialized biosimilars annually while delivering significant savings to healthcare systems around the world.

Biocon became a regular member of AAM in 2023 but joined the AAM’s Biosimilars Council back in 2016. Our AAM membership has enabled us to directly engage with other industry leaders who are at the forefront of biosimilar development, said Matthew Erick, Chief Commercial Officer – Advanced Markets, Biocon Biologics. Through working groups, and AAM’s Biosimilars Council, we are lending our voice as part of our commitment to the long-term sustainability of the biosimilars market.

Importantly, over the last two decades, Biocon’s commitment to ensuring the future of access to high-quality medicines has also included an investment of more than $1 billion in R&D and global-scale manufacturing. By advancing its biosimilars presence, Biocon Biologics strives to deliver affordable access to innovative and inclusive healthcare solutions, and ultimately, make a meaningful difference for patients and those charged with their care.

For more information, please visit

View All AAM Members


Jewel Smith

By Jewel Smith, Vice President, Membership and Operations
Published on September 13, 2023

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.